NorthLinks Bio Debuts With $34M to Build a New Antiviral Shield

BOSTON, MA – June 23, 2026 – The landscape of infectious disease prevention gained a significant new player today with the launch of NorthLinks Bio, a clinical-stage biotechnology company armed with $34 million in financing from RA Capital Management. The company is advancing a novel intranasal spray designed not to attack respiratory viruses directly, but to block the door they use to enter our bodies, a strategy that could prove resilient against the relentless evolution of influenza and other viral threats.

The launch marks a strategic reorganization of the UK-based Pneumagen Ltd. into a new US-headquartered entity, blending Scottish research ingenuity with the formidable biotech ecosystem of Boston. With its lead candidate, HEX17, having already shown promising results in early clinical trials, NorthLinks Bio is positioning itself to address a critical gap in our defenses against the seasonal and pandemic risks that define the 21st-century global health environment.

A New Frontier in Viral Defense

At the heart of NorthLinks Bio's strategy is a fundamental shift in antiviral design. For decades, the fight against viruses has been a reactive arms race, with vaccines and therapies targeting specific, and often rapidly mutating, viral proteins. NorthLinks Bio is pioneering a host-targeted approach with its proprietary glycan-targeted platform.

The company's lead candidate, HEX17, is an intranasal spray containing engineered carbohydrate-binding modules (CBMs). Instead of hunting a virus, HEX17 binds with high affinity to sialic acids—sugar molecules that coat the surface of human respiratory cells. These sialic acids are the universal docking stations for a host of pathogens, including influenza, respiratory syncytial virus (RSV), and various coronaviruses. By effectively masking these entry points, HEX17 creates a protective shield in the nasal passages, preventing viruses from gaining a foothold in the first place.

This approach carries profound implications. Because it targets a stable feature of the human host rather than a mutable part of the virus, HEX17 has the potential to be strain-agnostic and durable, maintaining its efficacy even as new viral variants emerge. This stands in stark contrast to the annual cat-and-mouse game of flu vaccine reformulation.

The science is not merely theoretical. HEX17 has successfully completed Phase 1 and Phase 2a clinical studies. A pivotal Phase 2 human challenge study (NCT05507567), the results of which were published in the peer-reviewed journal Infectious Diseases and Therapy, demonstrated that prophylactic administration of the spray resulted in an approximately 50% reduction in symptomatic influenza infection. The treatment was well-tolerated and also led to reductions in symptom severity and viral shedding, a level of efficacy comparable to approved antiviral drugs.

"Respiratory viruses continue to represent a significant global health burden despite the availability of vaccines and antiviral therapies," said Fanny Cavalié, the newly appointed CEO of NorthLinks Bio. "We believe there is a substantial opportunity for a convenient, broad-spectrum intranasal prophylactic capable of providing continuous protection across influenza strains and potentially other respiratory viruses."

The Strategic Play: From Scotland to Boston

The formation of NorthLinks Bio is as much a story of strategic finance and corporate evolution as it is of scientific innovation. The company emerges from Pneumagen, a 2016 spin-out from the University of St Andrews in Scotland, which nurtured the technology and guided HEX17 through its initial clinical successes.

The $34 million financing, led exclusively by the influential life sciences investor RA Capital Management, serves as the catalyst for this transformation. The reorganization establishes a new headquarters in Boston, placing NorthLinks Bio at the epicenter of global biotechnology, while shrewdly maintaining its core research operations in St Andrews. This transatlantic structure allows the company to tap into the deep well of US venture capital and clinical development expertise while preserving the scientific continuity and institutional knowledge from its Scottish origins.

Leading this new chapter is Fanny Cavalié, a Venture Partner at RA Capital's own Raven healthcare incubator. Her appointment signals RA Capital's deep conviction and hands-on approach to building its portfolio companies. The move is a classic playbook for accelerating a promising European technology onto the global stage, providing the capital and leadership necessary for large-scale clinical trials and commercial strategy.

Proceeds from the financing are earmarked for advancing HEX17 toward a critical Phase 2b readiness, scaling up manufacturing, and establishing the US operational base needed to conduct a global protection study across an entire flu season. Douglas Thomson, the former CEO of Pneumagen, will transition to the NorthLinks Bio Board of Directors, ensuring a seamless transfer of knowledge. "I am excited for the next stage of growth and to continue to support the company through it," Thomson stated.

The Prophylactic Promise for Public Health

While the science is sophisticated and the business strategy is sharp, the ultimate promise of HEX17 lies in its potential public health impact. The world has learned hard lessons about the limitations of a purely reactive stance to respiratory viruses. A convenient, self-administered nasal spray offering broad-spectrum protection could fundamentally alter personal and public health preparedness.

NorthLinks Bio is clear that HEX17 is not a replacement for vaccines. Instead, it is envisioned as a vital complementary tool. For the elderly, the immunocompromised, and those with underlying health conditions—populations for whom vaccines can be less effective—a daily prophylactic spray could offer an essential additional layer of defense during peak viral seasons. It also presents a potential solution for frontline healthcare workers, families with young children, or anyone seeking to minimize their risk during periods of high community transmission.

As Cavalié noted, "By targeting a validated host pathway, HEX17 is designed to provide broad protection that may remain resilient to viral evolution and support prophylactic use across respiratory virus seasons." This vision taps into a significant unmet need for continuous, on-demand protection that fits seamlessly into daily life.

Navigating a Crowded and Evolving Landscape

With its fresh funding and compelling scientific narrative, NorthLinks Bio enters a competitive but opportunity-rich field. The race to develop more effective and broader-spectrum antivirals has intensified, with major pharmaceutical firms and agile biotechs alike pursuing novel mechanisms. The company's key differentiator remains its host-targeted approach, which offers a compelling solution to the perennial challenge of viral drug resistance.

The immediate path forward involves executing a robust Phase 2b clinical program to confirm HEX17's efficacy across multiple viruses and in a real-world setting. Success in these trials will be the true test of its platform and the gateway to challenging the established paradigms of respiratory virus prevention. As NorthLinks Bio bridges the Atlantic, the global health and investment communities will be watching closely to see if this new shield can hold strong against the viral threats of tomorrow.